PTGX

Protagonist Therapeutics, Inc

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

2 insiders sold shares within a monthSince May 12, 2026+1.3

Trials

PTGXProtagonist Therapeutics, Inc.
1Calm
A Study of Rusfertide in Adults With Polycythemia Vera (PV)
Running, no new patientsPhase 3293 patientsMain results: Feb 21, 2025
PTGXProtagonist Therapeutics, Inc.
1Calm
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Running, no new patientsPhase 346 patientsMain results: Apr 1, 2026

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

12 sales (1 not pre-planned) · 0 purchases

Ali AsifChief Financial Officer · Sep 30, 2026Sold 12,595 sharesabout $1.8 million · pre-planned
Ali AsifChief Financial Officer · Sep 30, 2026Sold 46,034 sharesabout $6.5 million · pre-planned
PATEL DINESH V PH DPresident and CEO · Sep 10, 2026Sold 7,278 sharesabout $1.0 million · pre-planned
PATEL DINESH V PH DPresident and CEO · Sep 9, 2026Sold 63,548 sharesabout $9.3 million · pre-planned
PATEL DINESH V PH DPresident and CEO · Sep 8, 2026Sold 54,174 sharesabout $7.9 million · pre-planned
PATEL DINESH V PH DPresident and CEO · Aug 11, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.